Rationale Treatment-resistant depression (TRD) is a common clinical problem, often complicated with suicidal ideations and greater lifetime functional impairment, and represents a considerable challenge to management and treatment.
Introduction
Treatment-resistant depression (TRD) is a common clinical problem frequently associated with the greater suicidal ideation and attempts during the current episode and with the greater lifetime functional impairment . The management of TRD is a considerable challenge to the psychiatrists, as there are a few comparative data on the treatment options for TRD (Kennedy and Lam 2003) , because TRD represents exclusion criteria for the most antidepressant clinical trials (Dodd et al. 2005) .
Quetiapine is an atypical antipsychotic with a moderate affinity for 5-HT2A serotonergic, α1-adrenergic, muscarinic, and histaminergic receptors, a minor affinity for dopamine D2 and 5-HT1A receptor, and a low affinity for 5-HT2C, α2-adrenergic, and D1 receptors (DeVane and Nemeroff 2001) . It has a positive effect on the depressive symptoms in different psychiatric disorders (Adityanjee and Schulz 2002) . While atypical antipsychotics have been successfully applied in the TRD (Nemeroff 2005) , there are only a few data (Pathak et al. 2005; Devarajan et al. 2006) on the efficacy of quetiapine in TRD. Since the efficacy of quetiapine in TRD was retrospectively studied in ten adolescents (Pathak et al. 2005) , or in the naturalistic case series in six patients with TRD (Devarajan et al. 2006) , the aim of our study was to evaluate the efficacy and safety of quetiapine augmentation in the treatment-resistant adult inpatients with major depressive disorder (MDD) who were resistant to multiple antidepressant trials. We hypothesized that adding quetiapine to the current antidepressants would be a well-tolerated and effective treatment of TRD.
Materials and methods

Subjects
This was a prospective, open-labeled, noncomparative, flexible-dosed study that lasted 20 weeks. Patients (N=18) diagnosed with MDD, using structured clinical interview for DSM-IV disorders (American Psychiatric Association 1994), were recruited consecutively from the inpatients of the Department of Psychiatry of the Clinical Hospital Centre Zagreb, and 14 patients finished the study. All patients had signed informed consent, approved by the local Ethics Committee. The inclusion criteria were: (a) age ≥18 years, (b) MDD patients who have failed at least two antidepressant trials of different classes (Annath 1998) , with a minimum Hamilton rating scale for depression-17 items (HAMD) cut-off score of 20 (Hamilton 1960) , and (c) patients who have failed the mood stabilizer augmentation trial. The exclusion criteria were: (a) drugs of abuse disorder within the previous 6 months; (b) diagnosis of schizophrenia, schizoaffective disorder, dementia, posttraumatic stress disorder (PTSD), and bipolar I and bipolar II disorders; (c) presence of psychotic features (delusions or hallucinations in clinical interview, as specified in DSM-IV); (d) treatment with any antipsychotics for the current depressive episode; (e) pregnant or nursing women, or women in risk of becoming pregnant; and (f) duration of current depressive episode for less than 2 years, to exclude chronic depression. Comorbid chronic medical conditions (Table 1) were not the exclusion criteria, except the lifethreatening conditions. Quetiapine (mean dose was 315± 109 mg/day) was added to the current antidepressant treatment according to the usual dose-titration recommendation (the starting dose was 50 mg at bedtime, and was increased in 50 mg increments daily, up to the individual target dose, which was determined according to the safety and tolerability). All patients have continued taking their current antidepressant treatment regimen (Table 1) and flexible dose range of symptomatic benzodiazepine treatment if needed. Depressive symptoms, measured as total HAMD scores, and HAMD scores in the depressive mood subscale (item 1), insomnia subscale (items 4, 5, and 6), anxiety subscale (items 10 and 11) were evaluated at baseline, weekly during the first 9 weeks of treatment, and then after 12, 16, and 20 weeks of treatment. Responders had no serious adverse events. Three patients had hypotension, and two patients had daytime sedation, which were transient and mild in all cases.
Statistical analysis
Statistical evaluation of the all data, expressed as means± standard deviations (SD), was done using last observation carried forward analysis and with Kruskal-Wallis one-way analysis of variance on ranks and Dunn's test. The significance was accepted when p<0.05. All calculations were made with the statistical program Sigmastat (Jandel, version 2, Jandel, USA).
Results
Demographic and clinical characteristics of patients are presented in Table 1 . From the 18 patients, 14 were responders, 11 were remitters (i.e. with HAMD scores≤8), and 4 patients dropped out: one patient dropped out from the study due to the persistent hypotension and three patients dropped out due to the lack of response to quetiapine. Quetiapine add-on treatment significantly [χ 2 =178.92; df=12; p<0.001] reduced the total scores on the HAMD scale ( Fig. 1) in patients, and this effect was significant after 4-20 weeks of treatment. Quetiapine significantly [χ 2 =66.68; df=12; p<0.001] decreased the scores on the HAMD-insomnia subscale (items 4, 5, and 6), with a =86.36; df=12; p<0.001] response was observed in the HAMD-depressive mood subscale (item 1), with a significance achieved after 5-20 weeks of treatment (Fig. 3) . The anxiety scores on the HAMD (items 10 and 11) were significantly [χ 2 =113.10; df=12; p<0.001] lower after 4-20 weeks of treatment than at baseline (Fig. 4) .
Discussions
The add-on quetiapine treatment improved the clinical state in adult patients with TRD. The study was performed in naturalistic setting with the wide inclusion criteria. Most of our patients, due to their substantial burden of medical comorbidity, past suicide attempts, multiple drug resistance, and concomitant medical treatment, would not be included in the typical randomized, double-blind clinical trials; however, recently, it has been questioned (Tandon and Jibson 2003) whether the results of these trials might be applied to these refractory patients who are, in turn, frequently present in the clinical practice and are the most difficult to treat. The preliminary data from our study confirm that atypical antipsychotics are effective in TRD (Sharpley et al. 2003 (Sharpley et al. , 2005 Nemeroff 2005 ) and suggest that another atypical antipsychotic, quetiapine, as an add-on therapy, shows promise as a safe and effective therapeutic strategy for patients with TRD.
Quetiapine, added to the current antidepressant treatment, significantly reduced after 4-5 weeks the total scores and scores listed in the anxiety and depressive mood subscales on the HAMD in 18 TRD patients. From the 18 patients who entered the 20-week study, 14 were responders, 11 were remitters, and 4 patients dropped out due to the persistent hypotension and the lack of response to quetiapine. Our data agree with the beneficial effects of quetiapine in adolescents up to 18 years of age, who failed to respond to an 8-week treatment with selective serotonin reuptake inhibitors (SSRI) (Pathak et al. 2005) or with data on the quetiapine augmentation to sertraline, which improved the HAMD-21 rating scores and outcome in six TRD patients during 5-6 weeks (Devarajan et al. 2006) . The efficacy of quetiapine agrees with the reduction of depressive and anxiety symptoms in 11 patients with different anxiety disorders (Adson et al. 2004) or depressive symptomatology, aggression, hostility, mania, anxiety, delirium, PTSD (Adityanjee and Schulz 2002, Nemeroff et al. 2002) , and TRD (Devarajan et al. 2006) .
Sleep disturbances are common and severe symptoms of depression. In line with the data showing the sleepimprovement properties of olanzapine (Sharpley et al. 2005) or risperidone (Sharpley et al. 2003) in TRD, quetiapine was shown to improve sleep quality in TRD (present study), healthy volunteers (Cohrs et al. 2004) , and insomnia and nightmares in PTSD (Robert et al. 2005) . The beneficial effects of quetiapine on sleep in our study were significant after 2 weeks of treatment, which is in line with the reduction of early and middle insomnia in 11 patients with anxiety disorders after augmentation of quetiapine to SSRI (Adson et al. 2004 ). Sleep-improving properties of quetiapine might be achieved by its antihistaminergic (H1 receptors), dopaminergic (D1 receptors), and the α1-adrenergic receptor blocking properties.
The mechanism by which quetiapine's augmentation to the current antidepressant treatment improves depressive symptoms in TRD is still not clear, although quetiapine shows efficacy in treating depressive symptoms in different psychiatric illnesses (Adityanjee and Schulz 2002) . The combination of quetiapine and other antidepressant/s might have improved untreated residual psychopathology of these patients (Deverajan et al. 2006) . Quetiapine targets different neurotransmitter receptors (DeVane and Nemeroff 2001) affecting the brain regions that regulate anxiety and mood and downregulates the activity of the hypothalamicpituitary-adrenal (HPA) axis in healthy volunteers (Cohrs et al. 2006) . Because the overactivity of HPA axis is a characteristic feature of major depression, presumably, the beneficial antidepressant effect of quetiapine augmentation might be achieved via a downregulation of the HPA axis.
The study has several limitations such as the small number of patients and the open-labeled design, and the fact that quetiapine concentration was not measured, hence, the pharmacokinetic interaction with antidepressants cannot be ruled out. Its advantage was in a prolonged (20-week) treatment, an add-on therapy with quetiapine, and in inclusion of the TRD patients. In conclusion, the preliminary data on the quetiapine add-on therapy appear to have beneficial effects in TRD patients.
